Abstract
The literature on focal therapy is currently insufficient to recommend it as first-line treatment. We need information from both randomised controlled trials and prospective registries for every available energy. That said, important research is under way in this field, and the door should be kept open to an approach that has the potential to offer adequate cancer control with lower morbidity and better post-treatment quality of life in properly selected patients.
Original language | English |
---|---|
Pages (from-to) | 537-539 |
Number of pages | 3 |
Journal | European Urology |
Volume | 74 |
Issue number | 5 |
DOIs | |
State | Published - Nov 2018 |